Payment overview · 2025
General Payments
$380.58
19 reported records · 13 companies
Healthcare provider profile · identity verified
Shanthi Kumar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHESTERFIELD, MO · NPI 1497710651
Verified facts
What the public records show
CMS Open Payments records show Shanthi Kumar, M.D. received $380.58 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.81 | 15.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.72 | 15.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.88 | 12.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.41 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.98 | 7.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.81 | 7.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.87 | 6.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.96 | 5.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.67 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.83 | 4.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.25 | 4.3% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.92 | 4.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.47 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $380.58 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.88 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.98 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.98 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 497 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 120 |
| Losartan Potassium | Losartan Potassium | 365 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 286 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 64 |
| Potassium Chloride | Potassium Chloride | 238 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 57 |
| Metformin Hcl | Metformin Hcl | 201 | 62 |
| Lisinopril | Lisinopril | 195 | 50 |
| Alprazolam | Alprazolam | 190 | 62 |
| Furosemide | Furosemide | 190 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 185 | 48 |
| Omeprazole | Omeprazole | 170 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 44 |
| Trazodone Hcl | Trazodone Hcl | 159 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 53 |
| Gabapentin | Gabapentin | 148 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 31 |
| Simvastatin | Simvastatin | 100 | 25 |
| Donepezil Hcl | Donepezil Hcl | 97 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 54 |
| Meloxicam | Meloxicam | 85 | 23 |
| Sertraline Hcl | Sertraline Hcl | 80 | 19 |
| Tramadol Hcl | Tramadol Hcl | 80 | 17 |
| Memantine Hcl | Memantine Hcl | 79 | 17 |
| Allopurinol | Allopurinol | 78 | 22 |
| Carvedilol | Carvedilol | 78 | 17 |
| Eliquis | Apixaban | 76 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 75 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 34 |
| Spironolactone | Spironolactone | 65 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 46 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 41 |
| Atenolol | Atenolol | 55 | 17 |
| Buspirone Hcl | Buspirone Hcl | 54 | 13 |
| Montelukast Sodium | Montelukast Sodium | 53 | 15 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 12 |
| Famotidine | Famotidine | 48 | 15 |
| Ozempic | Semaglutide | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 17 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 13 |
| Valsartan | Valsartan | 46 | 14 |
| Ezetimibe | Ezetimibe | 45 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 18 |
| Januvia | Sitagliptin Phosphate | 45 | 13 |
| Metformin Hcl Er | Metformin Hcl | 45 | 16 |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 38 | 38 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 22 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Humalog | Insulin Lispro | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Cephalexin | Cephalexin | 23 | 15 |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Baclofen | Baclofen | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Prednisone | Prednisone | 15 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $380.58 · 19 records | Lilly USA, LLC | AREXVY, CAPVAXIVE, CREON, Cologuard Collection Kit, GARDASIL 9, GEMTESA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, OTEZLA, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, SHINGRIX, STRENSIQ, VYNDAQEL, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error